GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

2,015.00p
   
  • Change Today:
      11.00p
  • 52 Week High: 2,208.00
  • 52 Week Low: 1,344.00
  • Currency: UK Pounds
  • Shares Issued: 4,045.40m
  • Volume: 2,548,387
  • Market Cap: £81,515m
  • RiskGrade: 129
  • Beta: 0.00

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 3.3% 0.0%
Div Cover 2.6 2.5
Op Mrgn 24.3% 28.9%
ROCE 62.0%  
Latest F'cast
P/E 11.5 12.1
PEG 1.4 2.2
Pr/Revenue 2.5 2.6
Pr/Book 5.0  
Latest F'cast
Revenue 4.1% 3.5%
PBT 112.9% 32.2%
EPS 8.0% 3.8%
DPS 8.2% 8.3%

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%
31-Dec-25 32,667.00 7,401.00 172.00p 10.6 1.3 +8% 66.00p 3.6%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 33,823.83 9,783.35 178.55p 11.3 3.0 +4% 71.45p 0.0%
31-Dec-27 35,497.68 10,609.27 193.43p 10.4 1.2 +8% 75.30p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Total Voting Rights 01-Jul-2026 15:00 RNS
Holding(s) in Company 29-Jun-2026 15:00 RNS
Transaction in Own Shares 29-Jun-2026 15:00 RNS

GSK ShareCast News

GSK's momelotinib receives orphan drug designati... 12-Jun-2026 ShareCast
GSK to buy Boston-based biopharma firm Nuvalent ... 09-Jun-2026 ShareCast
Trials show GSK drug cures hepatitis B in nearly... 28-May-2026 ShareCast

GSK Top Newspaper Links

GSK to buy US cancer treatment firm Nuvalent for... 09-Jun-2026 Guardian
GSK signs £45m deal with UCL offshoot for liver ... 08-Jun-2026 Times
Strong vaccine sales deliver an early boost for ... 29-Apr-2026 Times

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
22-Jun-26 Buy Vishal Sikka 5,069.08p 1,266 £64,174.55
22-Jun-26 Buy Jeannie Lee 5,069.08p 802 £40,654.02
22-Jun-26 Buy Harry (Hal) C. Dietz 3,825.98p 667 £25,519.29

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 2,015.00p
Change Today 11.00p
% Change 0.55 %
52 Week High 2,208.00
52 Week Low 1,344.00
Volume 2,548,387
Shares Issued 4,045.40m
Market Cap £81,515m
Beta 0.00
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
6.98% above the market average6.98% above the market average6.98% above the market average6.98% above the market average6.98% above the market average
36.36% above the sector average36.36% above the sector average36.36% above the sector average36.36% above the sector average36.36% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 2
Buy 3
Neutral 11
Sell 2
Strong Sell 0
Total 18
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 14-May-26 19-Feb-26
Paid 09-Jul-26 09-Apr-26
Amount 17.00p 18.00p

Trades for 03-Jul-2026

Time Volume / Share Price
16:48 124 @ 2,015.00p
16:36 558 @ 2,015.00p
16:36 2,263 @ 2,015.00p
16:35 1 @ 2,015.00p
16:35 16,250 @ 2,015.00p

GSK Key Personnel

CEO Luke Miels

Top of Page